Antiproliferative activity of twenty-nine (E)-4-aryl-4-oxo-2-butenoic acid amides against three human tumor cell lines (HeLa, FemX, and K562) is reported. Compounds showed antiproliferative activity in one-digit micromolar to submicromolar concentrations. The most active derivatives toward all the cell lines tested bear alkyl substituents on the aroyl moiety of the molecules. Fourteen compounds showed tubulin assembly inhibition at concentrations <20 mM. The most potent inhibitor of tubulin assembly was unsubstituted compound 1, with IC 50 ¼ 2.9 mM. Compound 23 had an oral LD 50 in vivo of 45 mg/kg in mice. Cell cycle analysis on K562 cells showed that compounds 1, 2 and 23 caused accumulation of cells in the G2/M phase, but inhibition of microtubule polymerization is not the principal mode of action of the compounds. Nevertheless, they may be useful leads for the design of a new class of antitubulin agents.
Introduction
Chalcones, or 1,3-diaryl-2-propen-1-ones (I, Fig. 1 ), are considered as the intermediate precursors to all flavonoid compounds (II, Fig. 1 ). Diverse biological activities have been attributed to these compounds, in particular antioxidative [1] , antimalarial [2] , antileishmanial [3] , antiinflamatory [4] , and anticancer [5] properties. Numerous SAR studies of their anticancer activities have been described [6e9] . Chalcones that originate in plants have eOH and MeOe substitution on rings A and B, due to biosynthetic pathways [10] . Health benefits of natural chalcones can be ascribed to their redox properties and their ability to scavenge radical oxygen species [11] . Along with scavenging of free radicals, biological activity of chalcones can be ascribed to their ability to act as Michael acceptors with nucleophilic moieties, especially with the thiol groups of biological targets. So far, synthetic chalcones that exert antiproliferative activity bear mainly eOH, MeOe, and halogen substituents [12] . Alkyl substitution, especially on ring A, occurs relatively infrequently.
Chalcones and structurally similar compounds exert their antiproliferative activity through various mechanisms. For example, recently described chalcone-based compounds that are proteosome inhibitors probably act as covalent binders, involving their ketovinyl moiety [13] . It has been postulated that the presence of a 4-amino function on ring A of the chalcone structure, protonated at physiological pH, increases their reactivity and thus their antiproliferative activity [14, 15] . It has also been confirmed that Nalkylmaleimides exert antiproliferative activity by inhibition of topoisomerase I [16, 17] . This led to the design of the 4-aminochalcone maleamic acids (III) and imides (IV) [18] . Most of these derivatives exert antiproliferative activity in the low micromolar range. Moreover, it was shown that phenylcinnamides (V) bind to tubulin, causing inhibition of its polymerization and thereby altering the tubulinemicrotubule equilibrium [19] . Structurally similar cinnamoyl anthranilates (VI) also act as antitubulin agents [20] . In addition, another type of molecule containing the ketovinyl moiety, aroylacrylic acids (C, Scheme 1), exert antiproliferative activity toward HeLa cells [21a] and other human dedifferentiated cell lines [21b] .
This rationale led us to design chalconeearoylacrylic acid chimeras, by incorporation of the amidic moiety between the a,bunsaturated carbonyl moiety and the B ring of chalcones. We have synthesized twenty-nine aroylacrylic acid amides, tested their inhibitory potency on three tumor cell lines, and examined their effects on tubulin polymerization.
Results and discussion

Chemistry
The synthetic pathway to 1e29 is shown in Scheme 1. Friedele Crafts acylation of the commercially available substituted benzenes (A) with maleic acid anhydride (B) yielded aroylacrylic acids (C) [22] . Subsequently, the acids were converted to acid chlorides in dry THF by phosphorous oxychloride and then in situ reacted with equimolar amounts of aromatic or alicyclic amines to give the corresponding aroylacrylic acid amides (D). The coupling constants of vinylic protons ( 3 J HH ) of c.a. 15 Hz proved the E configuration of the double bond in all compounds (see characterization data within Section 5.1 Experimental/Chemistry). Along with this, the NOESY spectrum of compound 11 also proved the E configuration of the double bond. We chose this derivative due to the presence of parasubstituted aromatic rings, having a simple AA 0 BB 0 1 H NMR pattern. Distance between ortho-and meta-protons on the aroyl ring was used as reference. The eCH]CHe NOESY integral appears less than 1% of the chosen reference ( Figure S1 in Supplementary material), which also proved E geometry of the double bond. The same compound having Z geometry, as obtained by optimization on the semiempirical level of theory, showed significantly shorter distance of eCH]CHe protons, as expected ( Figure S2 in Supplementary material). Molecular geometry, as obtained by single crystal X-ray analysis (unpublished results), of derivative 12 also proved the E geometry of the double bond ( Figure S3 in Supplementary material). NMR spectra of representative compounds 7, 8, 9 and 23 are shown in Supplementary material, Figure S4 . During evaluation of the purity of compounds by HPLC analysis, we observed a trend between the retention times (RT) and virtual log P values (r ¼ 0.900, n ¼ 29). This finding will be examined in detail separately.
Antiproliferative activities of 1e29
Previously, we showed that aroylacrylic acids exert antiproliferative activity toward human tumor cell lines [21] at micromolar concentrations. The aim of this study was to investigate the effects of replacement of the carboxyl group with a cycloalkylamide or arylamide moiety. The presence of two aromatic rings bonded directly to each other or separated by one to four carbon atoms, so that they are spatially close but not coplanar, is a significant structural attribute of a number of anticancer compounds, especially antitubulin agents [23] .
We tested the antiproliferative activity of 1e29 on HeLa (human cervix carcinoma), FemX (human melanoma) and K562 (human chronic myelogenous leukemia) cells. The results are shown in Table 1 . Most of the compounds showed antiproliferative activity at (Table 1) . Reagents: (a) AlCl 3 in CH 2 Cl 2 ; (b) POCl 3 , dry THF. For compounds 8 and 17, cyclohexylamine was used to obtain the corresponding aroylacrylic acid amides (D). Benzylamine was used to obtain derivatives 9, 10, 15 and 17. For the rest of the compounds, aniline or substituted anilines were used.
lower concentrations as compared with similarly substituted aroylacrylic acids [21] .
HeLa cells were the least sensitive toward the newly synthesized compounds, with IC 50 values in the one-digit micromolar range for the majority of compounds. Compounds having alkyl substituents at positions 2 and 5 or at 2 and 4 on the aroyl phenyl ring (2, 12, 13, 14, and 22) exerted potency at submicromolar concentrations on the HeLa cells. A similar relationship between aroyl substitution and antiproliferative activity was observed for aroylacrylic acids [21] . The influence of structural variations of the amidic moiety on antiproliferative activity could not be interpreted in a straightforward manner, but we observed that more ovoid molecules, having larger apolar surface areas (ASA), displayed higher potency. Trends between ASA and an oval shape of the molecules and their potency toward HeLa cells are shown in Supplementary material, Figure S5a and b. We did not observe such a trend with the estimated virtual log P values [24] .
The majority of alkyl-substituted derivatives with unsubstituted phenyl groups at the amidic portion of the molecule exerted submicromolar activities toward the FemX cell line. The least active were unsubstituted 1 and derivatives with halogen or methoxy substituents (23e27) at the aroyl moiety. These compounds had IC 50 values above 2 mM. Generally, the presence of a 4-i-Pr substituent at the phenylamidic moiety of the molecules (5, 14, 18) slightly decreased antiproliferative activity in comparison with their unsubstituted counterparts. In most instances, 3,5-dimethoxy substitution on the amidic portion of the molecule had an unfavorable influence on antiproliferative activity. We did not observe other specific structural features that affected the antiproliferative potency of 1e29 toward FemX cells. The majority of the compounds contain phenylamide or 3,5-diMeO-phenylamide moieties. It should be noted that among the phenylamide derivatives (1e3, 6, 12, 20, 21, 23, 24e27) , compounds that have a more lipophilic aroyl moiety exerted a more pronounced antiproliferative activity toward all cell lines tested. We observed the same trend for 3,5-di-MeO-phenylamide derivatives (4, 7, 13, 16, 22, 28, 29) toward HeLa cells. Among the 3,5-di-MeOphenylamide derivatives, the less lipophilic derivatives exerted a more pronounced antiproliferative activity toward FemX and K562 cell lines (see for example 28 vs. 13). Due to the narrow range of IC 50 's toward FemX and K562 cells, this conclusion should be taken with caution.
A number of the compounds had submicromolar activity against all three cell lines examined. These were compounds 2, 12, 13, 14 and 22.
Inhibition of tubulin polymerization by 1e29 and cell cycle analysis
Turning to molecular mechanism of action, we first considered tubulin as a potential target, based on the structural similarity of 1e 29 with the known tubulin inhibitory activity of phenylcinnamides (V) [19] and cinnamoyl anthranilates (VI) [20] (Fig. 1) . Compounds 1e29 were compared with combretastatin A-4 as a reference compound for inhibition of tubulin assembly (Table 2) . values below 20 mM. The unsubstituted derivative 1 had the lowest IC 50 value (2.9 mM), while the other effective inhibitors all had small substituents on the aroyl moiety and no substituent on the phenylamide portion of the molecule. Compounds substituted on the phenylamide moiety (4-i-Pr, 3,5-di-MeO-) showed only weak inhibitory activity in the polymerization assay or were inactive. The halogen and methoxy substituted derivatives (23e27) that exerted inferior antiproliferative activities, as compared with other compounds, were relatively active as inhibitors of tubulin polymerization. Four (compounds 12, 13, 14 and 22) of the five best antiproliferative agents were inactive as antitubulin agents. Therefore, the SAR of 1e29 for the inhibition of tubulin polymerization was quite different from the SAR observed in the cancer cell line screen. Thirteen compounds that showed activity as inhibitors of tubulin polymerization were tested as inhibitors of colchicine binding, at 5 and at 50 mM (Table 2 ). All tested compounds showed some, albeit modest, inhibition of colchicine binding. The greatest inhibition of colchicine binding was observed with compounds 1, 2 and 23, which were also the three best inhibitors of tubulin polymerization. It is possible that these derivatives exert antitubulin activity by binding at the same site as colchicine, which was also observed with structurally similar antitubulin chalcones [26] .
Molecules that alter tubulin assembly in cells invariably cause alteration of cell cycle distribution, with preferential G2/M blockade. We therefore examined the mechanism of action of four of the newly synthesized derivatives (Table 3 and Figure S6 [20] ). Thus, it seems likely that there is another, more dominant molecular mechanism of action for our compounds through which they exert their antiproliferative activity. Our compounds are powerful Michael acceptors, acting as unsaturated ketones (kinetic study of the addition of the model thiol and amino compounds on representative congeners will be described elsewhere), so they probably also act as alkylating agents.
In vivo acute toxicity
Compound 23 was chosen for an in vivo acute toxicity test. This compound exerted both significant antiproliferative potency toward all cell lines tested and showed significant inhibition of tubulin polymerization. Compound 23 is also the only fluorosubstituted derivative in the set. The fluoro substituent at position 4 of the aroyl phenyl ring makes it, probably, more stable toward metabolic degradation by cytochromes (see, for example, [27] ). Due to insufficient water solubility and the absence of ionizable moieties amenable to prepare the salt, the compound was dissolved in DMSO and given orally to mice. The LD 50 value was 45 mg/kg. Further structural optimization is required to obtain less toxic compounds.
Molecular modeling
All compounds exert significant antiproliferative potency in low micromolar to submicromolar concentrations, spanning a narrow range of IC 50 values. A narrow range of activity values usually does not produce statistically significant correlations, so we did not perform a QSAR study for data on the antiproliferative potency of 1e29. Among 1e29, roughly, compounds having a solvent-assessable area <620 Å 2 and a volume <305 Å 3 inhibited tubulin polymerization with IC 50 values <20 mM (Table S7 in Supplementary material). The majority of tubulin assembly inhibitors that target the colchicine site, reported thus far, resemble colchicine or combretastatin A-4, bearing two or three MeO/OH substituents on the aromatic rings, which are connected by a twoto four-carbon spacer [23, 28] . Within 1e29, the unsubstituted compound or compounds bearing a small substituent at position 4 of the aryl moiety are the most potent inhibitors of tubulin polymerization and of colchicine binding. Also, an unsubstituted phenyl of the amidic moiety is preferred in our compound series. Therefore, in our modeling study, among compounds cocrystallized with tubulin, we chose the minimally substituted compounds E70, from the PDB entry 3HKC, and N16, from the PDB entry 3HKD [29] (structures in Figure S8 , Supplementary material) in their tubulin-bound, cocrystallized conformations, for comparison with compounds 1e3, 6, 8, 9, 17, 21, 20, and 23e27. The shape and the pharmacophoric pattern of the compounds were compared using the ROCS program [30] . We found a trend between pharmacophoric similarity with E70 of the set studied (OpenEye Color force field/ Explicit Meals-Dean [31] , Tanimoto scoring) and the percentage of inhibition of colchicine binding at 50 mM (r ¼ 0.89), with two outliers (17 and 24) ( Figure S9 in Supplementary material). It should be mentioned that pharmacophoric similarity between templates and compounds studied did not exceed 0.23 for E70 or 0.35 N16, as obtained with the Tanimoto function. Other statistically significant correlations or trends were not observed. Despite this, compounds 1, 2, and 23 were always highly ranked using a combined scoring function that includes both the shape and the pharmacophoric similarity (Tanimoto combo), having a score >0.80 for E70, and >1.00 for N16 ( Figure S10 in Supplementary material).
The Tanimoto combo score for all compounds studied exceed 0.62 for E70, and 0.95 for N16.
Conclusion
(E)-4-aryl-4-oxo-2-butenoic acid amides exert antiproliferative activity toward three human tumor cell lines (HeLa, FemX, and K562) with one-digit micromolar to submicromolar IC 50 values. All derivatives had antiproliferative activity that was significantly greater than that of their precursors, aroylacrylic acids. The replacement of the carboxyl group of aroylacrylic acids with an arylamide or cycloalkylamide moiety proved beneficial for antiproliferative activity. The most active derivatives toward all three cell lines tested were compounds with alkyl substituents on the aroyl moiety. Although fourteen compounds inhibited tubulin assembly with IC 50 values <20 mM, cell cycle analysis of compoundtreated K562 cells showed that only a few compounds caused accumulation of cells in the G2/M phase. The mode of action competitive to tubulin polymerization inhibition obviously exists. Nevertheless, the newly synthesized compounds may represent good leads for the design of a new class of antitubulin agents with the SAR data we obtained. The most potent inhibitor of tubulin polymerization was the compound unsubstituted on both the aroyl and the arylamido moieties, having an IC 50 ¼ 2.9 mM. Our data further indicate that bulkier substituents on both the aroyl and amidic moieties of the molecules impose steric hindrance for the binding of this class of compounds to tubulin. Structural modification to further test this hypothesis is underway.
Experimental
Chemistry
All chemicals were purchased from Fluka, Aldrich or Merck, having >98% purity, and were used as received. Melting points
were determined in open capillary tubes on an SMP-10 Stuart apparatus and are uncorrected. ESI-MS spectra were recorded on an Agilent Technologies 6210-1210 TOF-LC-ESI-MS instrument in positive mode. For HPLC analysis the Agilent HPLC system 1200 (equipped with vacuum degasser, binary pump, autosampler, thermostatted column compartment and DAD UV detector) with Zorbax Extend C18 column (RRHT, 50 Â 4.6 mm, 1.8 mm) was used.
Compounds were dissolved in MeOH (0.5 mg/mL), sample volume was 0.2 mL, column temperature was 40 C. The UV detector was set on 280 and 310 nm. Mobile phase A was 0.2% HCOOH in H 2 O, mobile phase B was MeCN. Gradient mode: 0e2 min 40% A: 60% B; 2e10 min 60% B e 100% B. All compounds had >99.5% purity.
1 H and 13 C NMR spectra were recorded in DMSO-d 6 or CDCl 3 on a Bruker AVANCE 500/125 MHz or a Varian Gemini2000 200/ 50 MHz instrument. NOESY spectrum of compound 11 was recorded on a Bruker AVANCE 500 instrument. Chemical shifts are reported in parts per million (ppm) relative to tetramethylsilane (TMS), and spin multiplicities are given as follows:
General procedure for synthesis of compounds is given under 2.1 Chemistry.
Characterization of compounds 1e29
(E)-4-oxo-4-phenyl-2-butenoic acid phenylamide (1)
C 16 H 13 NO 2 , starting from (E)-4-phenyl-4-oxo-2-butenoic acid (0.017 mol) and a corresponding amount of aniline, 1. 
(E)-4-(2,5-dimethylphenyl)-4-oxo-2-butenoic acid benzylamide (9)
C 19 H 19 NO 2 , starting from (E)-4-(2,5-dimethylphenyl)-4-oxo-2-butenoic acid (0.0078 mol) and a corresponding amount of benzylamine, as described above, 1.04 g of 9 was obtained, 45.41% yield, yellow solid, m.p. ¼ 142e144 C, (AcOEt). 1 
(E)-4-(4-isopropylphenyl)-4-oxo-2-butenoic acid (4-methoxyphenyl)amide (11)
C 20 H 21 NO 3 , starting from (E)-4-(4-isopropylphenyl)-4-oxo-2-butenoic acid (0.0078 mol) and a corresponding amount of 3,5-dimethoxyaniline, 0.71 g of 11 was obtained, 28.09% yield, yellow solid, m.p. ¼ 142e144 C, decomposition (AcOEt). 
(E)-4-(2,4-diisopropylphenyl)-4-oxo-2-butenoic acid (3,5-dimethoxyphenyl)amide (13)
C 24 H 29 NO 4 , starting from (E)-4-(2,4-diisopropylphenyl)-4-oxo-2-butenoic acid (0.0096 mol) and a corresponding amount of 3,5-dimethoxyaniline, 1.90 g of 13 was obtained, 50.00% yield, yellow solid, m.p. ¼ 120e122 C, decomposition (AcOEt). 1 [32] as modified by Ohno and Abe [33] , 72 h after compound addition. Briefly, 20 mL of MTT solution (5 mg/mL in phosphate buffered saline) was added to each well. Cells were incubated for 4 h at 37 C in a humidified atmosphere with 5% CO 2 .
Then, 100 mL of 10% SDS was added to each well. Absorbance was measured at 570 nm. Cell survival was measured/quantified using absorbance at 570 nm of a sample with cells grown in the presence of various concentrations of agent divided by the absorbance of the control sample (the absorbance of cells grown only in nutrient medium). Absorbance of blank was always subtracted from absorbance of a corresponding sample with cells. All experimentally obtained IC 50 data, reported in Table 1 , are means of at least three measurements done in triplicate. DNA content and cell cycle distribution were analyzed using a Becton Dickinson FAC-Scan flow cytometer. Flow cytometric analysis was performed using a CellQuestR (Becton Dickinson, San Jose, CA, USA) on a minimum of 10,000 cells per sample [34] .
Inhibition of tubulin polymerization and colchicine binding
The tubulin assembly and [ 3 H]colchicine binding assays were performed with electrophoretically homogenous bovine brain tubulin [35] . The assembly assay [36] was performed with 10 mM (1.0 mg/mL) tubulin, 0.8 M monosodium glutamate (pH 6.6 with HCl in a 2.0 M stock solution), 0.4 mM GTP, and 4% (v/v) dimethyl sulfoxide (as the compound solvent). Tubulin and varying compound concentrations were preincubated without GTP for 15 min at 30 C, samples were placed on ice, and GTP was added. The samples were transferred to 0 C cuvettes in Beckman DU7400 and DU7500 recording spectrophotometers equipped with electronic temperature controllers. After baselines were established at 350 nm, the temperature was jumped to 30 C (less than 1 min), and sample turbidity was followed for 20 min. The IC 50 was the compound concentration that reduced the turbidity reading at 20 min by 50%, relative to a control reaction mixture without compound. The colchicine binding assay was described in detail by VerdierPinard et al. [37] . The reaction mixtures contained a tubulin stabilizing buffer system [37] and 1.0 mM (0.1 mg/mL) tubulin, 5.0 mM at which time the reaction is about 40e60% complete in the absence of the compounds. The reactions were stopped with 3 mL of ice water, and each diluted reaction mixture was filtered through a stack of two DEAE-cellulose filters from Whatman. The amount of radiolabeled colchicine bound to the tubulin adsorbed to the filters was determined in a scintillation counter.
5.3.3. Acute toxicity 5.3.3.1. Animals. Male albino mice (NMRI Hann) weighing 18e22 g, obtained from VivariumeGalenika a.d. Belgrade, Serbia, selected by random sampling, were used in the study. They were housed under standard animal conditions, at 23 AE 2 C with 50% relative air humidity. The animals had free access to food (standard pallet diet) and water. This study was performed following the National ('The Law on the Experimental Animal Treatment', Republic of Serbia), and European (Directive 2010/63/EU; European convention for the protection of vertebrate animals used for experimental and other scientific purposes) regulations and standards. The acute toxicity tests were performed in accordance with OECD-423 guidelines. Experiments were approved by the Animal Ethics CommitteeGalenika a.d. (Permission No 3/12).
5.3.3.2.
Acute toxicity studies. 20 mg of compound 23 was dissolved in 10 mL of DMSO. The tested substance (dose level of 10 mg/ kg body weight) was given to mice by gavage. If mortality was not observed, the procedure was repeated with higher doses of 20, 30, 40, or 50 mg/kg body weight. If mortality was observed in 2 or 3, among 6 animals, then the dose administered was assigned as a toxic dose. If mortality was observed in one animal, the substance was applied again in the same dose, to confirm the toxic dose.
Following the administration of the tested substance, the animals were followed for signs of toxicity for 72 h. Observation was continued for 14 days. The toxic dose was confirmed as 45 mg/kg body weight for the oral route of administration.
Molecular modeling
The shape and the pharmacophoric pattern of compounds 1e3, 6, 8, 9, 17, 21, 20 , and 23e27 were compared with the ligands cocrystallized with tubulin. As templates for comparison we used compounds E70, from the PDB entry 3HKC [29] , and N16, from the PDB entry 3HKD [29] , in their cocrystallized conformations. 2D structures of templates are shown in Figure S7 in Supplementary material. Compounds E70 (N-{2-[(4-hydroxyphenyl)amino]pyridin-3-yl}-4-methoxy-benzenesulfonamide) and N16 ((3Z, 5S)-5-benzyl-3-[1-(phenylamino)ethylidene]pyrrolidine-2,4-dione) were extracted from the PDB files and hydrogens added in VegaZZ 2.4.0 [38] . Structures were saved as mol2 files. Up to 100 conformations of compounds 1e3, 6, 8, 9, 17, 21, 20 , and 23e27 were generated, from SMILES notation, in the OMEGA program [39], by using MMFF94s force field [40] (both to build initial structures and for search of the conformational space). To obtain 100 conformations per compound having four rotatable bonds in their backbone, rmsd options in OMEGA was set to 0.1. The set of conformers of each compound was saved as mol2 files. The ROCS program was used for the shape and for the pharmacophoric pattern comparison. The Tanimoto cut-off was set to À1. The 100 random starts and the explicit Meals-Dean force field, with modifications by OpenEye Inc., were used. The 3D dependent molecular properties of 1e29 (solvent-assessable area, polar surface area, apolar surface area, volume, virtual log P and ovality) were calculated for the minimumenergy conformation of each molecule, as obtained by OMEGA and MMFF94s force field, and by using a 1.4 Å probe (water), or 0 for volume, in VegaZZ. Only molecular properties that show some regularity in comparisons with antiproliferative or antitubulin activity are shown in Table S1 in Supplementary material. Structures of the E and the Z isomer of compound 11 were optimized in MOPAC2009 [41] , using PM6 semiempirical MO method [42] , with eigenvector-following optimizer to root-mean-square gradient >0.01 kcal/mol/Å.
